Department of Obstetrics and Gynaecology, Jinshan Hospital, Fudan University, Shanghai, China.
Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, China.
Int J Biol Markers. 2024 Sep;39(3):265-273. doi: 10.1177/03936155241265976. Epub 2024 Jul 23.
Cervical cancer is the most prevalent malignant tumor in women. This study aims to detect collagen type V α1 chain (COL5A1) expression and its clinical relevance in the prognosis of patients with cervical cancer.
Cervical cancer tissues and their paired adjacent normal tissues were prepared for tissue microarray. The expression of COL5A1 protein and the scores of the expression were evaluated by immunohistochemistry (IHC) staining. The prognostic value of COL5A1 was analyzed by R software version 4.2.1 with "survival, survminer, ggplot2" packages and Gene Expression Profiling Interactive Analysis (GEPIA). The cBioPortal database was utilized for the analysis of gene mutations.
COL5A1 protein was overexpressed in human cervical cancer tissues compared to their paired adjacent normal tissues detected by IHC ( < 0.001). High expression of COL5A1 tends to be in elderly patients with cervical cancer. Survival analyses of clinical data of patients with cervical cancer showed that a high level of COL5A1 expression was significantly correlated with shorter overall survival ( = 0.031) and disease-free survival ( = 0.042) of patients. Further analyses of The Cancer Genome Atlas-Cervical Squamous Cell Carcinoma and the GEPIA survival datasets confirmed the association of high COL5A1 expression with poor overall survival of patients ( = 0.040 and = 0.018, respectively). The analysis of genomic alterations of using the cBioPortal tool revealed that the gene was altered in 4% of cervical cancer patients and COL5A1 corresponding protein alterations with post-translational modifications were hydroxylation.
COL5A1 is a tissue biomarker correlated with the poor prognosis of patients with cervical cancer, which may lead to a new clinical application.
宫颈癌是女性最常见的恶性肿瘤。本研究旨在检测胶原蛋白 V 型 α1 链（COL5A1）在宫颈癌患者预后中的表达及其临床相关性。
制备宫颈癌组织及其配对的相邻正常组织的组织微阵列。通过免疫组织化学（IHC）染色评估 COL5A1 蛋白的表达及其表达评分。使用 R 软件版本 4.2.1 及其“survival、survminer、ggplot2”包和基因表达谱交互分析（GEPIA）分析 COL5A1 的预后价值。利用 cBioPortal 数据库分析基因的突变情况。
COL5A1 蛋白在人宫颈癌组织中的表达高于配对的相邻正常组织，经 IHC 检测（ < 0.001）。COL5A1 的高表达倾向于老年宫颈癌患者。对宫颈癌患者临床数据的生存分析表明，COL5A1 高水平表达与患者总生存（ = 0.031）和无病生存（ = 0.042）显著相关。对 The Cancer Genome Atlas-Cervical Squamous Cell Carcinoma 和 GEPIA 生存数据集的进一步分析证实了 COL5A1 高表达与患者总生存不良之间的关联（ = 0.040 和 = 0.018，分别）。使用 cBioPortal 工具对基因组改变的分析表明，在 4%的宫颈癌患者中改变了 基因，COL5A1 相应的蛋白改变与翻译后修饰的羟化有关。
COL5A1 是与宫颈癌患者不良预后相关的组织生物标志物，可能导致新的临床应用。
